Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has unveiled plans to invest £275m in its UK manufacturing network, and said that it views the country as an attractive location for investment despite last month's vote to leave the European Union.
Subscribe to our email newsletter
The investment will go to sites at Barnard Castle, Durham; Montrose in Angus, Scotland; and Ware in Hertfordshire.
At Barnard Castle, the company will spend £92m on a sterile facility to support the manufacture of existing and new biopharmaceutical assets in its pipeline.
GSK is investing around £110m in Montrose site to build a new facility for manufacturing respiratory active ingredients.
Coming to the third site in Ware, the company has allocated £74m for setting up additional manufacturing capacity to increase production of its new Ellipta respiratory inhaler.
Locals living around the three sites can expect new employment opportunities once the company begins its constructional activities.
On the latest investments, GSK CEO Andrew Witty said: “Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products.
"It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here. From their manufacture in the UK, many of these medicines will be sent to patients around the world.”
This multi-national pharma company headquartered in the historic town of Brentford, London has a total of nine sites in the UK with around 6000 employees.
Globally, the company has its presence in 115 countries, employing nearly 100,000 people for the manufacture of various drugs, vaccines along with consumer products.